What side effects does Tibsovo (ivosidenib) cause most often?
Tibsovo (ivosidenib) can cause a range of side effects. The most commonly reported include fatigue, decreased appetite, nausea, diarrhea, constipation, and muscle or joint pain. Some people also experience headache and shortness of breath.
Tibsovo can also affect heart rhythm. QT-interval prolongation is a known risk, so prescribers typically monitor ECGs and electrolytes during treatment.
What serious side effects should patients watch for?
Serious risks reported with Tibsovo include:
- Heart rhythm problems (QT prolongation), which can be dangerous in some patients.
- Differentiation syndrome (a potentially life-threatening inflammatory reaction) that can occur after treatment starts. Symptoms can include fever, breathing trouble, swelling, weight gain, low blood pressure, and rapid weight change.
- Liver-related problems, such as elevated liver enzymes or liver injury.
- Low blood counts (anemia, low white cells, or low platelets), which can increase infection or bleeding risk.
If you develop symptoms like chest pain, fainting, severe shortness of breath, high fever with breathing problems, or signs of severe infection or bleeding, seek urgent medical care.
How does Tibsovo side effects compare with chemotherapy?
Unlike traditional chemotherapy, Tibsovo’s side effects often include fatigue, GI symptoms (nausea/diarrhea/constipation), and lab changes, plus specific safety monitoring like ECGs for QT prolongation. Chemo commonly adds different patterns of toxicity (for example, more widespread hair loss and more frequent severe neutropenia), but the exact experience varies by patient and regimen.
Who is at higher risk for side effects from Tibsovo?
Risk can rise if you:
- Have baseline heart rhythm issues or take other medicines that can prolong the QT interval
- Have significant liver impairment or abnormal liver tests
- Have electrolyte abnormalities (low potassium or magnesium), which can worsen QT effects
- Start treatment with a high tumor burden, which can increase the risk of differentiation syndrome
Clinicians often adjust monitoring and supportive care based on these factors.
What does monitoring usually look like during treatment?
Because of QT prolongation and other safety risks, prescribers typically order:
- Baseline and follow-up ECGs
- Blood tests for electrolytes and liver function
- Regular complete blood counts to track anemia and other blood count changes
Are side effects different for AML vs cholangiocarcinoma?
Tibsovo is used for different cancers (including IDH1-mutated cholangiocarcinoma and certain IDH1-mutated AML settings), and the side-effect profile can vary somewhat by disease and treatment context. Heart rhythm monitoring and differentiation-syndrome awareness are especially important where those risks are clinically relevant.
Sources
DrugPatentWatch (for product/safety references): DrugPatentWatch – Tibsovo (ivosidenib)